300 related articles for article (PubMed ID: 30935847)
1. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
3. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
Washino S; Shirotake S; Takeshita H; Inoue M; Miura Y; Hyodo Y; Kagawa M; Izumi K; Oyama M; Kawakami S; Saito K; Matsuoka Y; Taniuchi S; Shintani A; Miyagawa T
Int J Clin Oncol; 2023 Dec; 28(12):1651-1658. PubMed ID: 37658926
[TBL] [Abstract][Full Text] [Related]
4. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
5. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
6. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y; Hamamoto S; Sugiyama Y; Tomiyama N; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Kubota H; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Yasui T; Kimura K
Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
[TBL] [Abstract][Full Text] [Related]
7. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
8. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Nukaya T; Takahara K; Yoshizawa A; Saruta M; Yano Y; Ohno T; Uchimoto T; Fukuokaya W; Adachi T; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Hirasawa Y; Hashimoto T; Komura K; Inamoto T; Miki J; Kimura T; Ohno Y; Azuma H; Shiroki R
Clin Genitourin Cancer; 2024 Feb; 22(1):76-83. PubMed ID: 37880020
[TBL] [Abstract][Full Text] [Related]
10. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K
JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T
Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659
[TBL] [Abstract][Full Text] [Related]
12. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
[TBL] [Abstract][Full Text] [Related]
15. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
16. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
[TBL] [Abstract][Full Text] [Related]
17. Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome.
Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Horii A
Cancer Med; 2023 Nov; 12(22):20810-20820. PubMed ID: 37902133
[TBL] [Abstract][Full Text] [Related]
18. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
19. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]